Tag:
Tufts Center for Drug Development
Latest Headlines
Latest Headlines
CNS drug developers face long stretch in the clinic, poor odds of success
The exodus of Big Pharma companies from the CNS drug development field has put a bright spotlight on the hurdles any developer faces when tackling a tricky disease like Alzheimer's.
Analysis: Grim stats on CNS drugs demand fresh approach to development
It's no secret that neuropsychiatric diseases like schizophrenia, depression and Alzheimer's present one of the toughest challenges to drug developers. Ken Kaitin and Christopher Milne at the Tufts
Report: Approval success rates higher for smaller firms
The top 10 pharmaceutical companies out of the world's top 50 have lower estimated overall clinical approval success rates than do smaller firms in that group, according to a report completed by the
